Effects of enalapril, losartan, and verapamil on blood pressure and glucose metabolism in the Cohen-Rosenthal diabetic hypertensive rat

Hypertension
Talma RosenthalA Cohen

Abstract

We undertook the present study to examine the effect of the angiotensin-converting enzyme inhibitor enalapril, the angiotensin II antagonist losartan, and calcium antagonist verapamil on systolic pressure and spontaneous blood glucose levels in rats from the Cohen-Rosenthal diabetic hypertensive strain. Genetic hypertension and diabetes developed in this strain after crossbreeding of Cohen diabetic and spontaneously hypertensive rats. The new rat strain was fed their usual copper-poor sucrose diet, which is essential for the development of this model, and for 4 weeks received either enalapril, losartan, or verapamil. Systolic pressure was reduced significantly compared with controls in all treated groups. Chronic treatment with enalapril or verapamil, but not with losartan, succeeded in lowering spontaneous blood glucose, indicating improved diabetic control. Data suggest that angiotensin-converting enzyme inhibition by enalapril, but not angiotensin II antagonism by losartan, can improve glucose metabolism in addition to its hypotensive effect in a genetic diabetic hypertensive rat strain. This confirms that the drop in glucose with converting enzyme inhibition is highly dependent on bradykinin accumulation. Data further sugge...Continue Reading

References

Apr 1, 1979·The American Journal of Clinical Nutrition·J HallfrischS Reiser
Apr 1, 1977·Scandinavian Journal of Clinical and Laboratory Investigation·K Hermansen, J Iversen
May 14, 1992·European Journal of Pharmacology·K MizunoS Fukuchi
Sep 1, 1992·The Journal of Clinical Investigation·R A LafayetteT W Meyer
Jun 1, 1991·Diabetes Care·P P Stein, H R Black
Jan 1, 1991·European Journal of Clinical Pharmacology·M Busch SørensenJ Lyngsøe
Sep 1, 1990·Diabetic Medicine : a Journal of the British Diabetic Association·T SeefeldtO Schmitz
Aug 1, 1986·British Journal of Clinical Pharmacology·C G SempleK R Paterson
Apr 1, 1988·Metabolism: Clinical and Experimental·C E Mondon, G M Reaven
May 1, 1983·British Journal of Clinical Pharmacology·C G SempleA R Lorimer
May 1, 1981·Metabolism: Clinical and Experimental·J B Young, L Landsberg
Jan 1, 1993·Journal of Cardiovascular Pharmacology·S GambardellaG Menzinger
Apr 1, 1994·British Medical Bulletin·A H Barnett
Jun 1, 1995·Diabetes Research and Clinical Practice·A A KaymazA S Büyükdevrim
Jan 1, 1995·Clinical and Experimental Pharmacology & Physiology. Supplement·Y Erlich, T Rosenthal
Jan 1, 1995·Clinical and Experimental Pharmacology & Physiology. Supplement·T RosenthalA Cohen

❮ Previous
Next ❯

Citations

Feb 13, 1999·European Journal of Pharmacology·J DuarteA Zarzuelo
Apr 29, 1998·Journal of Cardiovascular Pharmacology·Y Erlich, T Rosenthal
Jan 22, 2008·American Journal of Nephrology·Junya JiaPravin C Singhal
Jun 15, 2007·Journal of Cardiovascular Pharmacology and Therapeutics·Talma RosenthalFrancesco Amenta
Feb 14, 2003·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Nish ChaturvediUNKNOWN DIRECT Programme Study Group
Aug 28, 2020·Frontiers in Pharmacology·Marcos Fernandes GregnaniRonaldo C Araujo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.